853910-61-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-2-[4-[3-methyl-2-oxo-8-[(pyridin-3-yl)ethynyl]-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile is used as a potential pharmaceutical agent for its possible biological activities. Its complex molecular structure may contribute to specific therapeutic effects, although further research is needed to understand its exact uses and effects.
Used in Organic Chemistry:
In the field of organic chemistry, 2-Methyl-2-[4-[3-methyl-2-oxo-8-[(pyridin-3-yl)ethynyl]-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile may serve as a building block or intermediate in the synthesis of other complex organic compounds. Its unique structure could be utilized to create novel molecules with specific properties.
Used in Biochemistry:
2-Methyl-2-[4-[3-methyl-2-oxo-8-[(pyridin-3-yl)ethynyl]-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile could be employed in biochemistry for studying molecular interactions and mechanisms. Its complex structure may allow it to bind to specific biological targets or enzymes, providing insights into biological processes and potential therapeutic applications.

Upstream product

• 2510-23-8 3-Ethynylpyridine 
• 915019-50-0 2-[4-(8-bromo-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-2-methyl-propionitrile 
• 1610681-28-1 2-methyl-2-(4-(2-oxo-8-(pyridin-3-ylethynyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile 
• 74-88-4 methyl iodide 

Relevant academic research and scientific papers

Establishment of a structure-activity relationship of 1 H-imidazo[4,5-c]quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness

Compound NVP-BEZ235 (1) is a potent inhibitor of human phospoinositide-3- kinases and mammalian target of rapamycin (mTOR) that also showed high inhibitory potency against Trypanosoma brucei cultures. With an eye toward using 1 as a starting point for ant

Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway

Imidazo[4,5-c]quinoline derivatives have been discovered and developed as potent and effective modulators of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) pathway to lead to clinical development candidates. The SAR data of representative examples of this compound class and their biological profiling in cellular and in vivo settings are presented and discussed.

1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.